## Abstract
Navigating regulatory pathways is critical for IVD manufacturers entering global markets. This application note compares FDA 510(k), CE-IVD (EU IVDR), and NMPA (China) registration requirements for POCT devices, providing a practical framework for regulatory strategy planning.
## Introduction
The global IVD market is highly regulated, with each major market requiring distinct approval pathways. Understanding these requirements early in product development can save months of delays and significant costs. This guide focuses on POCT devices including lateral flow assays, molecular diagnostics, and immunoassay analyzers.
## FDA 510(k) Pathway (United States)
### Overview
The FDA 510(k) premarket notification demonstrates that a device is substantially equivalent to a legally marketed predicate device.
### Key Requirements
– Predicate device identification
– Performance comparison studies
– Clinical data (if required)
– Quality system compliance (21 CFR Part 820)
– Registration and listing
### Timeline and Cost
– Timeline: 3-6 months (standard), 30 days (abbreviated)
– Cost: $15,000-$50,000 (excluding consulting fees)
– User fee (FY2026): $13,410 (small business: $3,352)
### Common Pitfalls
– Inadequate predicate selection
– Insufficient performance data
– Missing biocompatibility studies
## CE-IVD Marking (European Union – IVDR)
### Overview
The EU In Vitro Diagnostic Regulation (IVDR) 2017/746 replaced the IVDD in May 2022, introducing stricter classification and conformity assessment requirements.
### Classification Rules
– Class A (low risk): Self-declaration
– Class B (low-moderate risk): Notified Body review
– Class C (moderate-high risk): Notified Body review + clinical evidence
– Class D (high risk): Full Notified Body assessment
### Technical Documentation
– Device description and specifications
– Risk management (ISO 14971)
– Performance evaluation (Annex XIII)
– Clinical evidence
– Post-market surveillance plan
### Timeline and Cost
– Timeline: 12-18 months (Class C/D)
– Cost: €50,000-€200,000 (Notified Body fees + consulting)
– Annual surveillance audits required
### Common Pitfalls
– Underestimating clinical evidence requirements
– Incomplete performance evaluation reports
– Lack of post-market surveillance infrastructure
## NMPA Registration (China)
### Overview
China’s National Medical Products Administration (NMPA) requires registration for all IVD devices, with classification similar to EU IVDR.
### Classification
– Class I: Filing (low risk)
– Class II: Registration (moderate risk)
– Class III: Registration (high risk)
### Key Requirements
– Product technical requirements (PTR)
– Type testing by NMPA-designated labs
– Clinical evaluation (or exemption)
– Quality management system inspection
– Local authorized agent
### Timeline and Cost
– Timeline: 12-24 months (Class II/III)
– Cost: ¥200,000-¥800,000 (testing + consulting)
– Type testing: 3-6 months
### Common Pitfalls
– Inadequate local representation
– Type testing failures due to specification mismatches
– Clinical evaluation gaps
## Comparative Summary
| Aspect | FDA 510(k) | CE-IVD (IVDR) | NMPA |
|——–|————|—————|——|
| Timeline | 3-6 months | 12-18 months | 12-24 months |
| Cost | $15K-$50K | €50K-€200K | ¥200K-¥800K |
| Clinical Data | Sometimes | Required (Class C/D) | Required (Class II/III) |
| QMS Audit | Yes (FDA inspection) | Yes (Notified Body) | Yes (NMPA inspection) |
| Local Agent | US Agent | EU Authorized Rep | China Agent Required |
## Strategic Recommendations
### For Startups
1. Start with FDA 510(k) if US market is primary target
2. Leverage FDA clearance for CE-IVD and NMPA submissions
3. Budget 18-24 months for global market entry
### For Established Manufacturers
1. Parallel submissions where feasible
2. Use common technical documentation structure
3. Invest in QMS that meets all three jurisdictions
### For POCT Devices Specifically
1. Consider waived status (FDA CLIA) for true point-of-care use
2. Address specimen type claims early (fingerstick, venous, etc.)
3. Plan for usability studies (human factors)
## Conclusion
Regulatory strategy should be integrated into product development from day one. While the pathways differ, core principles remain consistent: demonstrate safety, performance, and quality. Due Bio supports IVD manufacturers with regulatory-ready documentation and technical files for all major markets.
## About Due Bio
Due Bio provides OEM/ODM POCT solutions including lateral flow strips, TRF immunoassay analyzers, and microfluidic PCR systems with comprehensive regulatory support documentation.